Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SLXP > SEC Filings for SLXP > Form 8-K on 27-Feb-2014All Recent SEC Filings

Show all filings for SALIX PHARMACEUTICALS LTD

Form 8-K for SALIX PHARMACEUTICALS LTD


27-Feb-2014

Results of Operations and Financial Condition, Other Events, Financial


Item 2.02. Results of Operations and Financial Condition.

On February 27, 2014, Salix Pharmaceuticals, Ltd. (the "Company") issued a press release announcing its operating results for the fourth quarter and fiscal year ended December 31, 2013. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

The information in this Item 2.02 and the press release attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 8.01. Other Events.

Napo Litigation

The Company announced on February 25, 2014 that a New York State Supreme Court jury entered a verdict in its favor in a lawsuit filed against it by Napo Pharmaceuticals Inc. relating to Fulyzaq™(crofelemer). The jury specifically found that the Company complied with its contractual obligations in commercializing Fulyzaq (crofelemer) in the United States, and thus did not breach the license agreement between the parties. A copy of the press release announcing the results of this litigation is attached hereto as Exhibit 99.2.

Agreement with RedHill

The Company and RedHill Biopharma Ltd. ("RedHill") today announced that they have entered into an exclusive agreement by which the Company has licensed the worldwide exclusive rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments. A copy of the joint press release issued by the Company and RedHill announcing this agreement is attached hereto as Exhibit 99.3.

Financial terms of the transaction include an upfront payment of $7 million and $5 million in subsequent milestone payments to RedHill. The Company also has agreed to pay RedHill tiered royalties on net sales, ranging from low single-digit up to low double-digits. Under the worldwide license agreement, the parties also agreed on potential strategic collaboration with regard to certain other Company products in specific territories.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
  No.        Description

99.1         Press release issued by Salix Pharmaceuticals, Ltd. on February 27,
             2014.

99.2         Press release issued by Salix Pharmaceuticals, Ltd. on February 25,
             2014.

99.3         Joint press release issued by Salix Pharmaceuticals, Ltd. and RedHill
             Biopharma Ltd. on February 27, 2014.


  Add SLXP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SLXP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.